MFN, EU JCA & Equitable access: How 2026 will reshape global pharma and biotech
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Unfollow podcast failed
MFN, EU JCA & Equitable access: How 2026 will reshape global pharma and biotech
-
Narrated by:
-
By:
In this episode of The Growth Blueprint, Senior Partners Christian Schuler and Robert Dumitrescu discuss how global pharma and biotech are being transformed by Most Favored Nation pricing, Europe’s new Joint Clinical Assessment framework, and the growing focus on equitable access. Together they explore how these trends affect global pricing, evidence generation, launch strategy, and BD&L. Discover practical steps companies can take to adapt portfolios, access strategies, and deal structures for 2026 and beyond. For more resources, please visit: https://www.simon-kucher.com/
adbl_web_anon_alc_button_suppression_t1
No reviews yet